News
A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and ...
News Medical on MSN1d
GLP1 agonists linked to depression risk in new genetic studyA groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists-widely used in blockbuster ...
About The Study: Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 ...
Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...
HealthDay on MSN1d
GLP-1 RAs, SGLT2 Inhibitors May Reduce Risk for Alzheimer Disease, Dementia in T2DMBoth glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are ...
Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.
Once-daily orforglipron was more effective than placebo and just as safe as injectable GLP-1s in patients with diabetes and ...
HealthDay on MSN8d
2018 to 2022 Saw Increase in GLP-1 Receptor Agonist Use in Adults Without DiabetesTHURSDAY, April 10, 2025 (HealthDay News) — Among U.S. adults without diabetes, the use of glucagon-like peptide 1 receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback